Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in severe eosinophilic asthma (SWIFT-1)
NCT04719832Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of depemokimab in severe eosinophilic asthma (SEA), sponsored by GSK. Started Mar 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
severe eosinophilic asthma (SEA)
Beyond the preview
Go deeper on NCT04719832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04719832.